Cargando…

Serum TSH level as predictor of Graves’ disease recurrence following antithyroid drug withdrawal: A systematic review

Graves’ disease (GD) has a high recurrence rate despite various and adequate treatment. Numerous studies have been performed to identify the predictor of disease recurrence. This report aims to investigate the role of thyroid stimulating hormone (TSH) level as a thyrotropin in predicting the recurre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subekti, Imam, Kartiko, Gracia Jovita, Suhardi, Zahra Farhanni, Muhadi, Wisnu, Wismandari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845983/ https://www.ncbi.nlm.nih.gov/pubmed/33513181 http://dx.doi.org/10.1371/journal.pone.0245978

Ejemplares similares

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease
por: Liu, Jia, et al.
Publicado: (2017)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

The role of high fat diet on serum uric acid level among healthy male first degree relatives of type 2 diabetes mellitus
por: Purnamasari, Dyah, et al.
Publicado: (2023)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
por: Wisnu, Wismandari, et al.
Publicado: (2021)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
por: Kwon, Hyemi, et al.
Publicado: (2016)

Seventy-Two Hour Mortality Prediction Model in Patients with Diabetic Ketoacidosis: A Retrospective Cohort Study
por: Siregar, Nia Novianti, et al.
Publicado: (2018)

Carotid Intima Media Thickness in Graves Disease: Comparing Overt Hyperthyroid and Remission State
por: Nurjannah, Intan, et al.
Publicado: (2021)

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study
por: Karmisholt, J., et al.
Publicado: (2019)

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
por: Liu, Xiaomei, et al.
Publicado: (2015)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

THU670 Serum TSI Concentration In Patients With Graves’ Disease Undergoing Maintenance-dose Of Antithyroid Drug (ATD) And Its Relationship With Disease Relapse After ATD Withdrawal
por: Nhat Nguyen, Phong Vu, et al.
Publicado: (2023)

SAT460 Higher TSH Receptor Antibody At Diagnosis And Younger Age Predict Recurrence of Graves' Thyrotoxicosis After Thionamide Withdrawal At 10 Years
por: Wilson Gibb, Fraser, et al.
Publicado: (2023)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Antithyroid treatment improves thrombocytopenia in a young patient with Graves’ disease
por: Faienza, Maria Felicia, et al.
Publicado: (2020)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

MON-589 Prognostic Predictors of Initial Response of Graves' Disease to Antithyroid Drugs: A Single Center Experience
por: Alaghoury, Aliaa, et al.
Publicado: (2019)

Positive Antithyroid Antibodies and Nonsuppressed TSH Are Associated with Thyroid Cancer: A Retrospective Cross-Sectional Study
por: Krátký, Jan, et al.
Publicado: (2018)

Cross-sectional investigation of serum creatine kinase concentration in Graves disease patients treated with oral antithyroid drugs
por: Cheng, Ying, et al.
Publicado: (2020)

Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease
por: Gill, Harinder, et al.
Publicado: (2010)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment
por: Lee, Je-Sang, et al.
Publicado: (2021)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Differences in the Treatment Response to Antithyroid Drugs versus Electroconvulsive Therapy in a Case of Recurrent Catatonia due to Graves' Disease
por: Saito, Takahiro, et al.
Publicado: (2012)

Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
por: Belsing, Tina Z, et al.
Publicado: (2010)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"
por: Kim, Minsun
Publicado: (2021)

Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse
por: Wong, Tsz Wai Catherine, et al.
Publicado: (2022)

Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves’ disease: a systemic review
por: Xie, Qingxing, et al.
Publicado: (2023)

Clinical diagnosis of Graves’ or non-Graves’ hyperthyroidism compared to TSH receptor antibody test
por: Bell, Lauren, et al.
Publicado: (2018)

Factors Predicting Time to TSH Normalization and Persistence of TSH Suppression After Total Thyroidectomy for Graves' Disease
por: Paragliola, Rosa Maria, et al.
Publicado: (2019)

Non-MAS Non-APS Rare Case: Co-Occurrence of Graves’ Disease (GD), Latent Autoimmune Diabetes in Adult (LADA), Systemic Lupus Erythematosus (SLE), and Ulcerative Colitis (UC)
por: Harris, Laura, et al.
Publicado: (2021)

The thyroid function of Graves' disease patients is aggravated by depressive personality during antithyroid drug treatment
por: Fukao, Atsushi, et al.
Publicado: (2011)

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”
por: Kim, Ji Hyun
Publicado: (2022)

Antithyroid drugs
por: Jastrzębska, Helena
Publicado: (2015)

Antithyroid Drugs
por: Abdi, Hengameh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aa122lokjokurh8jbekvm8rl6e